Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial
| Autor: | Sandra González Maldonado, Erna Motsch, Stefan Delorme, Rudolf Kaaks, Philipp A. Schnabel, Hans-Ulrich Kauczor, Anthony B. Miller, Anke Trotter, Claus P. Heussel, Nikolaus Becker, Hendrik Dienemann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Randomization Lung Neoplasms Population law.invention 03 medical and health sciences 0302 clinical medicine Sex Factors Randomized controlled trial law Internal medicine Germany medicine Humans Mass Screening Prospective Studies Mortality Lung cancer education Lung Early Detection of Cancer Aged education.field_of_study business.industry Incidence (epidemiology) Incidence Hazard ratio Smoking Cancer Middle Aged medicine.disease Survival Analysis Oncology 030220 oncology & carcinogenesis Female business Tomography X-Ray Computed Lung cancer screening Follow-Up Studies |
| Zdroj: | International journal of cancerReferences. 146(6) |
| ISSN: | 1097-0215 |
| Popis: | In 2011, the U.S. National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these first findings from European trials that started in parallel with the NLST. The German Lung cancer Screening Intervention (LUSI) is a randomized trial among 4,052 long-term smokers, 50-69 years of age, recruited from the general population, comparing five annual rounds of LDCT screening (screening arm; n = 2,029 participants) with a control arm (n = 2,023) followed by annual postal questionnaire inquiries. Data on lung cancer incidence and mortality and vital status were collected from hospitals or office-based physicians, cancer registries, population registers and health offices. Over an average observation time of 8.8 years after randomization, the hazard ratio for lung cancer mortality was 0.74 (95% CI: 0.46-1.19; p = 0.21) among men and women combined. Modeling by sex, however showed a statistically significant reduction in lung cancer mortality among women (HR = 0.31 [95% CI: 0.10-0.96], p = 0.04), but not among men (HR = 0.94 [95% CI: 0.54-1.61], p = 0.81) screened by LDCT (pheterogeneity = 0.09). Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men. This heterogeneity could be the result of different relative counts of lung tumor subtypes occurring in men and women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text